2898-95-5

Usage

Uses

Used in Pharmaceutical Industry:
Cholan-24-oic acid, 3,7-dihydroxy-, Monosodium salt, (3a,5b,7b)is used as a therapeutic agent for the treatment of various liver diseases. Its application is primarily due to its ability to inhibit the uptake of toxic bile acids, such as deoxycholic acid, which can cause liver damage and apoptosis in hepatocytes. By reducing the levels of these harmful bile acids, Cholan-24-oic acid, 3,7-dihydroxy-, Monosodium salt, (3a,5b,7b)helps protect liver cells and promote their regeneration.
Additionally, Cholan-24-oic acid, 3,7-dihydroxy-, Monosodium salt, (3a,5b,7b)has been found to be effective in the treatment of primary biliary cirrhosis, a chronic liver disease characterized by the progressive destruction of small bile ducts. Formulations containing this bile acid derivative have been used to alleviate the symptoms and slow the progression of the disease.
Used in Research Applications:
Cholan-24-oic acid, 3,7-dihydroxy-, Monosodium salt, (3a,5b,7b)is also used as a research tool in the study of bile acid metabolism, liver function, and the development of novel therapeutic strategies for liver diseases. Its unique properties and effects on bile acid transporters make it a valuable compound for investigating the mechanisms underlying liver injury and the potential for developing new treatments to protect and repair liver tissue.

InChI:InChI=1/C24H40O4.Na/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26;/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28);/q;+1/p-1/t14-,15+,16-,17-,18?,19?,20+,22?,23+,24-;/m1./s1

Upstream product

• 128-13-2 ursodeoxycholic acid 

Downstream Products

• 77060-26-5 3-keto-7β-hydroxy-5β-cholan-24-oic acid 
• 78919-26-3 3β,7β-dihydroxy-5β-cholan-24-oic acid 

Relevant academic research and scientific papers

Synthesis, characterization and biological activity of hydroxyl- bisphosphonic analogs of bile acids

Bisphosphonates (BPs) are now the most widely used drugs for diseases associated with increased bone resorption, such as osteoporosis, and tumor bone diseases. A significant drawback of the BPs is their poor oral absorption that is enhanced by the presence of bile acid substituents in the bisphosphonate framework, with no toxic effects. A straightforward synthesis of bile acid-containing hydroxy-bisphosphonates and a full characterization of these pharmaceutically important molecules, including an evaluation of affinity and the mechanism of binding to hydroxyapatite, is presented. The biological activity of bile acid-containing bisphosphonate salts was determined using the neutral-red assay on the L929 cell line and primary cultures of osteoclasts. The bioactivity of the new compounds was found superior than bisphosphonates of established activity.

Dansyl-labeled cholic acid as a tool to build speciation diagrams for the aggregation of bile acids

Bile acids (BAs) are a family of natural steroids biosynthesized from cholesterol in the liver that tend to form aggregates in solution. A fluorescent derivative of cholic acid, namely 3α-Dns-ChA, was employed as a reporter to establish the speciation diagrams of the most abundant BAs that can be found mainly in three microenvironments, solution, and primary and secondary aggregates. The developed methodology is based on the analysis of the combined steady-state and time-resolved experiments performed on 3α-Dns-ChA whose emission behavior was found to be strongly medium dependent. In particular, speciation diagrams of sodium glycocholate (NaGCh), sodium taurocholate (NaTCh), sodium chenodeoxycholate (NaCDCh), sodium glycochenodeoxycholate (NaGCDCh), sodium deoxycholate (NaDCh), and sodium ursodeoxycholate (NaUDCh) were successfully built up.